An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
Adeno-associated virus (AAV) vectors have been successfully applied in hemophilia clinical trials. However, this approach is limited to patients without AAV-neutralizing antibodies (NAbs). In this study, we explored the feasibility of AAV re-administration in hemophilia A dogs treated initially 8 ye...
Main Authors: | Junjiang Sun, Wenwei Shao, Xiaojing Chen, Elizabeth P. Merricks, Lauren Wimsey, Yasmina L. Abajas, Glenn P. Niemeyer, Clinton D. Lothrop, Paul E. Monahan, R. Jude Samulski, Timothy C. Nichols, Chengwen Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-09-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050118300755 |
Similar Items
-
Chimeric Mice Engrafted With Canine Hepatocytes Exhibits Similar AAV Transduction Efficiency to Hemophilia B Dog
by: Wenwei Shao, et al.
Published: (2022-01-01) -
Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity
by: Xiaolei Pei, et al.
Published: (2020-09-01) -
AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life
by: Bhavya S. Doshi, et al.
Published: (2024-03-01) -
Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog
by: Lucas Van Gorder, et al.
Published: (2023-12-01) -
Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction
by: Junjiang Sun, et al.
Published: (2022-08-01)